Bioactivity of Recombinantly Expressed Human Serglycin Under Different Glycemic Conditions
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background Human platelet lysate (hPL) is clinically used for chronic wound treatment, yet therapeutic responses remain variable due to the undefined roles of individual platelet-derived components. Serglycin (SRGN) is abundant in platelet granules, but its function in diabetic wound repair is poorly understood. This study investigated the bioactivity of recombinant human serglycin (rhSRGN) in an in vitro model of diabetic re-epithelialization. Results SRGN cDNA was amplified from THP-1-derived mRNA, cloned into an expression vector, and transfected into HEK293T cells for recombinant protein production. Secreted rhSRGN was purified from conditioned media via immobilized metal affinity chromatography using a C-terminal 6×His tag. Western blotting confirmed that rhSRGN carried multiple glycosaminoglycan chains, including heparan sulfate, chondroitin sulfate, and dermatan sulfate. Functionally, rhSRGN (10 ng/mL) significantly enhanced keratinocyte migration under hyperglycemic conditions in a wound closure assay. Conclusions Recombinant serglycin promotes keratinocyte migration in a hyperglycemic microenvironment, supporting its potential as a defined platelet-derived biologic for bioengineered therapies targeting diabetic wound healing.
